Human Patents (Class 424/142.1)
  • Patent number: 10391100
    Abstract: The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 27, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Mark Manfredi
  • Patent number: 10344088
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 9, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • Patent number: 10323083
    Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: June 18, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
  • Patent number: 10307472
    Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 4, 2019
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jan C. Schmollinger
  • Patent number: 10288616
    Abstract: Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 14, 2019
    Assignees: Expression Pathology, Inc., The University Of Chicago
    Inventors: Daniel Catenacci, Todd Hembrough, Fabiola Cecchi, Wei-Li Liao
  • Patent number: 10253097
    Abstract: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: April 9, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Larry R. Pease, Virginia Van Keulen, Bogolub Ciric
  • Patent number: 10238698
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 26, 2019
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W. K. Alfred Yung, Amy Heimberger
  • Patent number: 10195273
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 5, 2019
    Assignee: SNIPR TECHNOLOGIES LIMITED
    Inventor: Jasper Clube
  • Patent number: 10166303
    Abstract: The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: January 1, 2019
    Assignee: Panacea Pharmaceutical Inc.
    Inventors: Hossein A. Ghanbari, Steven Andrew Fuller
  • Patent number: 10094835
    Abstract: This document provides methods and materials for treating patients following an assessment of immune subtypes such as an assessment of peripheral blood phenotypes. For example, methods and materials for treating a mammal having a medical condition after assessing a mammal's level of CD14+/DR? cells (e.g., CD14+/DR? monocytes) and level of CD4+ cells (e.g., CD4+ T cells) and classifying the mammal has being likely to experience a favorable or unfavorable medical outcome based at least in part on the mammal's level of CD14+/DR? cells and level of CD4+ cells are provided.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: October 9, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Allan B. Dietz, Michael P. Gustafson, Yi Lin
  • Patent number: 10066004
    Abstract: Inhibitor peptides for combinatorial inactivation of ErbB1, ErbB2, and ErbB3 featuring an EGFR-based peptide and a cell penetrating component such as a protein transduction domain (e.g., PTD4) for enhancing penetration of the EGFR-based peptide into a cell. The EGFR peptide may be from 8 to 30 amino acids in length. The inhibitor peptides can inhibit tumor growth, reduce metastasis, activate apoptosis, activate necrosis, disrupt calcium signaling, and/or increase ROS. In some embodiments, the EGFR-based peptide is at least 50% identical to at least 8 consecutive residues of SEQ ID NO: 1.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: September 4, 2018
    Assignee: ARIZONA CANCER THERAPEUTICS, LLC
    Inventor: Joyce A. Schroeder
  • Patent number: 10005845
    Abstract: An antibody or antigen-binding fragment thereof which specifically binds the ?3 domain of a HLA-G protein, in particular binds the ?2-microglobulin free HLA-G protein exhibiting an ?3 domain. The nucleic acid molecules encoding a human HLA-G ?3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to HLA-G proteins, and/or improving or treating conditions showing HLA-G+ lesions, and/or improving or treating a neoplasic condition or disease. A method of producing the antibody or antigen-binding fragment thereof, immunogenic compositions for use to elicit in a host an immune response against the ?3 domain of HLA-G protein, and an in vitro method for detecting HLA-G protein in a sample are also described.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: June 26, 2018
    Assignee: INVECTYS
    Inventors: Maria de las Nieves Loustau, Julien Caumartin, Pierre Langlade-Demoyen
  • Patent number: 9999624
    Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti-N3pGlu Abeta monoclonal antibody.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: June 19, 2018
    Assignee: Eli Lilly and Company
    Inventors: Patrick Cornelious May, Dustin James Mergott
  • Patent number: 9994629
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: June 12, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Karuppiah Muthumani, Niranjan Sardesai, Seleeke Flingai
  • Patent number: 9902770
    Abstract: Broadly neutralizing interferon-? and interferon-? antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFN? and IFN?.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 27, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Patent number: 9890212
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 13, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 9890215
    Abstract: The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: February 13, 2018
    Assignees: KING'S COLLEGE LONDON, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Randolph J. Noelle
  • Patent number: 9872921
    Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: January 23, 2018
    Assignee: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
    Inventors: Gregory R. Moe, Charles Paul Plested
  • Patent number: 9856320
    Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: January 2, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok Kumar Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 9827310
    Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 28, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Daly, Douglas MacDonald, Xunbao Duan
  • Patent number: 9821059
    Abstract: The present invention relates to a composition for stabilizing TNF?-binding protein exhibiting physiological activity, and more specifically, to a composition for stabilizing protein including basic amino acid and sugar and/or ammonium salt, a pharmaceutical formulation including the same, and a method for stabilizing TNF?-binding protein. The formulation including basic amino acid; and sugar and/or ammonium salt according to the present invention effectively inhibits aggregation, denaturation and oxidation of TNF?-binding protein used for treating various diseases, for example, an anti-TNF-alpha antibody, such that the protein is capable of being preserved and stored for a long time, which is widely usable and effective in a medical field using TNF?-binding protein, for example, an anti-TNF-alpha antibody.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: November 21, 2017
    Assignee: ALTEOGEN INC.
    Inventors: Soon Jae Park, Hye-Shin Chung, Jin Hwan Kim, Minsoo Byun, Ji Hyeon Yeon
  • Patent number: 9718890
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 1, 2017
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Patent number: 9708399
    Abstract: Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: July 18, 2017
    Assignee: ABBVIE, INC.
    Inventors: Chen Wang, Germano Coppola, Chris Chumsae
  • Patent number: 9708398
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: July 18, 2017
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Jaume Pons, Arnon Rosenthal
  • Patent number: 9688752
    Abstract: The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: June 27, 2017
    Assignee: AbbVie Inc.
    Inventors: Chen Wang, Germano Coppola, Chris Chumsae
  • Patent number: 9597411
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: March 21, 2017
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Patent number: 9593042
    Abstract: Embodiments of a glass-based article including a first surface and a second surface opposing the first surface defining a thickness (t) of about 3 millimeters or less (e.g., about 1 millimeter or less), and a stress profile, wherein all points of the stress profile between a thickness range from about 0·t up to 0.3·t and from greater than 0.7·t, comprise a tangent that is less than about ?0.1 MPa/micrometers or greater than about 0.1 MPa/micrometers, are disclosed. In some embodiments, the glass-based article includes a non-zero metal oxide concentration that varies along at least a portion of the thickness (e.g., 0·t to about 0.3·t). In some embodiments, the concentration of metal oxide or alkali metal oxide decreases from the first surface to a point between the first surface and the second surface and increases from the point to the second surface. The concentration of the metal oxide may be about 0.05 mol % or greater or about 0.5 mol % or greater throughout the thickness.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: March 14, 2017
    Assignee: Corning Incorporated
    Inventors: Guangli Hu, Charlene Marie Smith, Zhongzhi Tang, Steven Alvin Tietje
  • Patent number: 9539258
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 10, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
  • Patent number: 9512220
    Abstract: The present invention relates to antibodies against angiopoietins 1 and 2, and derivatives of these antibodies. More specifically, the present invention relates to therapeutic use of the antibodies and fragment thereof which specifically bind to angiopoietins 1 and 2.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: December 6, 2016
    Assignee: NEOPHARM CO., LTD.
    Inventors: Eunkyung Lee, Hyunjung Kang, Minhee Kim, Eun hye Park
  • Patent number: 9409995
    Abstract: PTK modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyper-proliferative disorders are provided.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: August 9, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
  • Patent number: 9381244
    Abstract: The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: July 5, 2016
    Assignees: KING'S COLLEGE LONDON, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Randolph Noelle
  • Patent number: 9375475
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 28, 2016
    Assignees: Board of Regents, The University of Texas System, Memorial Sloan-Kettering Cancer Center
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • Patent number: 9346879
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: May 24, 2016
    Assignee: AbbVie Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Christopher Chumsae
  • Patent number: 9335320
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: May 10, 2016
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Lori Friedman
  • Patent number: 9273125
    Abstract: Purified polypeptide is proposed, the amino acid sequence of which is essentially identical to the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:3, the polypeptide binding low density lipoproteins (LDL) and/or oxidized LDL (oxLDL), in particular LDL cholesterol and/or oxidized LDL cholesterol (oxLDL cholesterol). The invention includes the use of the polypeptide in combination with conventional adjuvants and/or carrier substances for producing a drug having a fat-reducing effect and for producing drugs for treating renal diseases.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: March 1, 2016
    Assignee: Patrys Limited
    Inventor: Heinz Peter Vollmers
  • Patent number: 9221915
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: December 29, 2015
    Assignees: Pfizer Inc., Amgen Fremont Inc.
    Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • Patent number: 9206427
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: December 8, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., CONICET, Fundacion Sales
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
  • Patent number: 9085618
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimxental, are also provided.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: July 21, 2015
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9073994
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 7, 2015
    Assignees: Ono Pharmaceutical Co., LTD.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Patent number: 9067999
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: June 30, 2015
    Assignees: Ono Pharmaceutical Co., LTD.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Patent number: 9067992
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 30, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg
  • Patent number: 9051371
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 9, 2015
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Publication number: 20150147335
    Abstract: The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treating hidradenitis suppurativa in a subject.
    Type: Application
    Filed: May 28, 2014
    Publication date: May 28, 2015
    Inventors: Martin M. Okun, Thomas C. Harris
  • Publication number: 20150147326
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 28, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki University
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20150147336
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: Yihong YAO, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
  • Patent number: 9040041
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 26, 2015
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
  • Publication number: 20150140085
    Abstract: Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.
    Type: Application
    Filed: June 26, 2013
    Publication date: May 21, 2015
    Applicant: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Publication number: 20150139948
    Abstract: The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 21, 2015
    Inventors: Manoj C. DESAI, Allen Yu HONG, Hon Chung HUI, Hongtao LIU, Randall W. VIVIAN, Lianhong XU
  • Publication number: 20150139987
    Abstract: Treatment of homozygous familial hypercholesterolemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an MTP inhibitor, an apoB-100 synthesis inhibitor, or a PCSK9 inhibitor.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Robert L. Martin, Charles A. McWherter, Patrick J. O'Mara